POP-OUT | CLOSE

An Information Portal to 105097 Biological Macromolecular Structures

 
{2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl}acetic acid
 
LUR is found in 3 entries
LUR
  •   Chemical Component Summary   Hide
    Name {2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl}acetic acid
    Identifiers 2-[2-[(2-chloranyl-6-fluoranyl-phenyl)amino]-5-methyl-phenyl]ethanoic acid
    Synonyms Lumiracoxib
    Formula C15 H13 Cl F N O2
    Molecular Weight 293.72 g/mol
    Type non-polymer
    Isomeric SMILES
    InChI
    InChI key KHPKQFYUPIUARC-UHFFFAOYSA-N
     
  •   Drug Info: DrugBank Hide
    DrugBank ID DB01283   (Stereoisomeric match)
    Name Lumiracoxib
    Groups
    • approved
    • investigational
    Description Lumiracoxib is a COX-2 selective inhibitor non-steroidal anti-inflammatory drug. On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling the drug.
    Synonyms
    • 2-((2-chloro-6-Fluorophenyl)amino)-5-methylbenzeneacetic acid
    • COX 189
    • COX-189
    • COX189
    • Lumiracoxibum
    • Prexige
    [more]
    Brand names Prexige
    Affected organism Humans and other mammals
    Indication For the acute and chronic treatment of the signs and symptoms of osteoarthritis of the knee in adults.
    Pharmacology Lumiracoxib has a different structure from the standard COX-2 inhibitors (e.g. celecoxib). It more closely resembles the structure of diclofenac (one chlorine substituted by fluorine, the phenylacetic acid has another methyl group in meta position), making it a member of the arylalkanoic acid family of NSAIDs. It binds to a different site on the COX-2 receptor than the standard COX-2 inhibitors. It displays extremely high COX-2 selectivity.
    Mechanism of action The mechanism of action of lumiracoxib is due to inhibition of prostaglandin synthesis via inhibition of cyclooygenase-2 (COX-2). Lumiracoxib does not inhibit COX-1 at therapeutic concentrations.
    Route of administration Oral
    Categories Cyclooxygenase 2 Inhibitors
    ATC-Code M01AH06
    AHFS-Code 28:08.04.08
    CAS number 220991-20-8
    Targets
    Name Sequence search Pharmacological action Actions
    Prostaglandin G/H synthase 1   Search  yes inhibitor
    Prostaglandin G/H synthase 2   Search  yes inhibitor
     
Ligand Image